Granted Patent
B2
US 12,680,139 · App. 18/442,036 · Granted Jul 14, 2026
Cancer biomarkers
Inventors:
Steven Stone (Salt Lake City, UT); Alexander Gutin (Salt Lake City, UT); Susanne Wagner (Salt Lake City, UT); Julia Reid (Salt Lake City, UT)
Assignee:
Myriad Genetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Claims (11)
1 . A method of analyzing a tumor sample, consisting essentially of:
extracting RNA from a tumor sample from a patient with prostate cancer and reverse transcribing the RNA to cDNA;
amplifying the cDNA of (i) a set of marker genes consisting of 10-30 marker genes comprising at least NUSAP1 and UBE2C and (ii) one or more housekeeping genes; and
determining an expression level for each gene in the set of marker genes.
2 . The method of claim 1 , wherein the set of marker genes additionally comprises ZWILCH.
3 . A method of analyzing a tumor sample, comprising:
(a) obtaining a sample comprising prostate cancer tumor tissue from a patient; and
(b) determining the expression of a panel of genes comprising NUSAP1 and UBE2C and no more than 30 total marker genes in the sample comprising prostate cancer tumor tissue;
wherein the patient is a candidate for active surveillance or actively surveilled when the expression of the genes NUSAP1 and UBE2C in the sample is not higher than the expected expression of the genes NUSAP1 and UBE2C in prostate cancer tumor tissue from a reference population, or
wherein the patient is a candidate for an active treatment selected from one or more of hormonal therapy, chemotherapy, radiation therapy, and surgery when the expression of the genes NUSAP1 and UBE2C in the sample is higher than the expected expression of the genes NUSAP1 and UBE2C in prostate cancer tumor tissue from a reference population.
4 . The method of claim 3 , wherein the panel of genes further comprises ZWILCH.
Assignments (2)
SECURITY INTEREST
Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 15, 2024
From: STONE, STEVEN; GUTIN, ALEXANDER; WAGNER, SUSANNE; REID, JULIA
To: MYRIAD GENETICS, INC.
Reel/Frame 066476/0001 →
Continuity (12)
Continuation
PCTUS2010020397
· Jan 7, 2010
Provisional Application
61256443
· Oct 30, 2009
Provisional Application
61241748
· Sep 11, 2009
Provisional Application
61185901
· Jun 10, 2009
Provisional Application
61179650
· May 19, 2009
Provisional Application
61143077
· Jan 7, 2009
References Cited (223)
US 5993388A
· Kattan et al.
· 1999
[cited by applicant]
US 6409664B1
· Kattan et al.
· 2002
[cited by applicant]
US 7056674B2
· Baker et al.
· 2006
[cited by applicant]
US 7081340B2
· Baker et al.
· 2006
[cited by applicant]
US 7569345B2
· Cobleigh et al.
· 2009
[cited by applicant]
US 7598031B2
· Liew et al.
· 2009
[cited by applicant]
US 7622251B2
· Baker et al.
· 2009
[cited by applicant]
US 7666595B2
· Rubin et al.
· 2010
[cited by applicant]
US 7695913B2
· Cowens et al.
· 2010
[cited by applicant]
US 7723033B2
· Baker et al.
· 2010
[cited by applicant]
US 7767391B2
· Scott et al.
· 2010
[cited by applicant]
US 7871769B2
· Baker et al.
· 2011
[cited by applicant]
US 7914988B1
· Chudin et al.
· 2011
[cited by applicant]
US 7930104B2
· Baker et al.
· 2011
[cited by applicant]
US 8110363B2
· Chudin et al.
· 2012
[cited by applicant]
US 8338109B2
· Vasmatzis et al.
· 2012
[cited by applicant]
US 20030235816A1
· Slawin et al.
· 2003
[cited by applicant]
US 20040014059A1
· Liew
· 2004
[cited by applicant]
US 20050064455A1
· Baker et al.
· 2005
[cited by applicant]
US 20050244872A1
· Harris
· 2005
[cited by applicant]
US 20050272644A1
· Chung et al.
· 2005
[cited by applicant]
US 20070026424A1
· Powell et al.
· 2007
[cited by applicant]
US 20070059720A9
· Fuqua et al.
· 2007
[cited by applicant]
US 20070099209A1
· Clarke et al.
· 2007
[cited by applicant]
US 20070128599A1
· Ridder et al.
· 2007
[cited by applicant]
US 20070128636A1
· Baker et al.
· 2007
[cited by applicant]
US 20070253953A1
· Chen et al.
· 2007
[cited by applicant]
US 20080275652A1
· Sotiriou et al.
· 2008
[cited by applicant]
US 20090048266A1
· Heise
· 2009
[cited by examiner]
US 20090123925A1
· Collie-Duguid et al.
· 2009
[cited by applicant]
US 20090215054A1
· Carter et al.
· 2009
[cited by applicant]
US 20090258795A1
· Cowens et al.
· 2009
[cited by applicant]
US 20090297500A1
· Nakamura et al.
· 2009
[cited by applicant]
US 20090299640A1
· Ellis et al.
· 2009
[cited by applicant]
US 20090305277A1
· Baker et al.
· 2009
[cited by applicant]
US 20090311702A1
· Shak et al.
· 2009
[cited by applicant]
US 20100130377A1
· Vasmatzis et al.
· 2010
[cited by applicant]
US 20100184041A1
· Baker et al.
· 2010
[cited by applicant]
US 20100184063A1
· Tsao et al.
· 2010
[cited by applicant]
US 20100196902A1
· Pestano et al.
· 2010
[cited by applicant]
US 20100222229A1
· Cobleigh et al.
· 2010
[cited by applicant]
US 20100267032A1
· Baker et al.
· 2010
[cited by applicant]
US 20100284908A1
· Rohlff et al.
· 2010
[cited by applicant]
US 20100324116A1
· Kruse
· 2010
[cited by applicant]
US 20110123990A1
· Baker et al.
· 2011
[cited by applicant]
US 20110129833A1
· Baker et al.
· 2011
[cited by applicant]
US 20110166838A1
· Gehrmann et al.
· 2011
[cited by applicant]
US 20110178374A1
· Baker et al.
· 2011
[cited by applicant]
US 20120028264A1
· Shak et al.
· 2012
[cited by applicant]
US 20120039805A1
· Lisanti et al.
· 2012
[cited by applicant]
US 20120041274A1
· Stone et al.
· 2012
[cited by applicant]
US 20120053842A9
· Gehrmann et al.
· 2012
[cited by applicant]
US 20120108453A1
· Smit et al.
· 2012
[cited by applicant]
US 20120109535A1
· Chudin et al.
· 2012
[cited by applicant]
US 20120190565A1
· Lisanti et al.
· 2012
[cited by applicant]
EP 2404998A2
· 2012
[cited by applicant]
EP 2409989A1
· 2012
[cited by applicant]
WO WO2004065583A2
· 2004
[cited by applicant]
WO WO2004074518A1
· 2004
[cited by applicant]
WO WO2004111603A2
· 2004
[cited by applicant]
WO WO2005007830A2
· 2005
[cited by applicant]
WO WO2005039382A2
· 2005
[cited by applicant]
WO WO2005100606A2
· 2005
[cited by applicant]
WO WO2006052731A2
· 2006
[cited by applicant]
WO WO2006052862A1
· 2006
[cited by applicant]
WO WO2006119593A1
· 2006
[cited by applicant]
WO WO2006135886A2
· 2006
[cited by applicant]
WO WO2007067672A2
· 2007
[cited by applicant]
WO WO2007070621A2
· 2007
[cited by applicant]
WO WO2008058018A2
· 2008
[cited by applicant]
WO WO2008077165A1
· 2008
[cited by applicant]
WO WO2008082730A2
· 2008
[cited by applicant]
WO WO2008103971A2
· 2008
[cited by applicant]
WO WO2008115419A2
· 2008
[cited by applicant]
WO WO2008151072A1
· 2008
[cited by applicant]
WO WO2009032915A2
· 2009
[cited by applicant]
WO WO2009045115A1
· 2009
[cited by applicant]
WO WO2009114836A1
· 2009
[cited by applicant]
WO WO2009140304A1
· 2009
[cited by applicant]
WO WO2009158620A2
· 2009
[cited by applicant]
WO WO2010003771A1
· 2010
[cited by applicant]
WO WO2010080933A1
· 2010
[cited by applicant]
WO WO2010119126A2
· 2010
[cited by applicant]
WO WO2010127322A1
· 2010
[cited by applicant]
WO WO2011063274A2
· 2011
[cited by applicant]
WO WO2011097509A2
· 2011
[cited by applicant]
WO WO2012006447A2
· 2012
[cited by applicant]
WO WO2012012225A2
· 2012
[cited by applicant]
WO WO2012030840A2
· 2012
[cited by applicant]
WO WO2012106718A2
· 2012
[cited by applicant]
WO WO2012122626A1
· 2012
[cited by applicant]
WO WO2012135008A1
· 2012
[cited by applicant]
WO WO2012152800A1
· 2012
[cited by applicant]
WO WO2012152811A1
· 2012
[cited by applicant]
WO WO2013028554A2
· 2013
[cited by applicant]
WO WO2014078700A1
· 2014
[cited by applicant]
Als et al., “Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer”, Clinical Cancer Research, vol. 13, No. 15, Aug. 1, 2007, pp. 4407-44…
[cited by applicant]
Desmedt, C., et al., “Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series,” Clinical Cancer Research, 13: 3207-32…
[cited by applicant]
Kuhl et al., “Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer,” Biomark. Med. (2022) 16(6):449-459.
[cited by applicant]
Phillips et al., “Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis”, Cancer Cell, vol. 9, Mar. 2006, pp. 157-173.
[cited by applicant]
Schmidt et al., “The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer”, Cancer Research, vol. 68, No. 13, 2008, pp. 5405-5413.
[cited by applicant]
“Active Surveillance for Prostate Cancer” by Memorial Sloan Kettering Cancer Center retrieved from https://www.mskcc.org/cancer-care/types/prostate/treatmenVactive-surveillance on Feb. 3, 2021 (6 pages).
[cited by applicant]
“Observation or Active Surveillance for Prostate Cancer”, American Cancer Society, retrieved from www.cancer.org/cancer/prostate-cancer/treating/watchful-waiting .html (Year: 2019).
[cited by applicant]
AFFYMETRIX GeneChip Human Genome Arrays Data Sheet, 2003.
[cited by applicant]
Affymetrix U95 Set. Retrieved on Oct. 22, 2015 from the internet: hllps://www.affymetrix.com/user/login.jsp?toURL=/analysis/netaffx/showresults.affx#.
[cited by applicant]
Affymetrix U95 Set. Retrieved on Oct. 22, 2015 from the internet: https://www.affymethx.com/user/login.jsptoURL=/analysis/netaffx/showresults.affx#.
[cited by applicant]
Affymetrix website search results. Retrieved on May 8, 2015 from: https://www.affymetrix.com/analysis/netafrx/ xmlquery.affx?netaffx=netaffx4_annot&_requestid=118226#.
[cited by applicant]
Affymetrix website search results. Retrieved on May 8, 2015 from: https://www.affymetrix.com/analysis/nelaffx/xmlquery.affxnelaffx=nelaffx4_annol&_requeslid=118226#.
[cited by applicant]
Bedolla et al., “Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation”, Clinical Cancer Research, vol. 13, Jul. 1, 2007, pp. 3860-3867.
[cited by applicant]
Beer et al., “Gene-expression profiles predict survival of patients with lung adenocarcinoma”, Nature Medicine, 2002, vol. 8, pp. 816-824.
[cited by applicant]
Beresford et al., “Measuring proliferation in breast cancer: practicalities and applications,” Breast Cancer Research, Nov. 30, 2006, Retrieved from internet: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1797032/ pd…
[cited by applicant]
Bibikova et al. “Expression Signatures That Correlated With Gleason Score and Relapse in Prostate Cancer,” Genomics, Apr. 24, 2007, vol. 89, Iss. 6, pp. 666-672.
[cited by applicant]
Bibikova et al., “Expression signatures that correlated with Gleason score and relapse in prostate cancer”, Genomics, Jun. 2007, vol. 89, No. 6, pp. 666-672.
[cited by applicant]
Carter et al., “A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers”, Nature Genetics, vol. 38, No. 9, Sep. 2006, pp. 1043-1048.
[cited by applicant]
Chan et al. G&P magazine. 2006. 6(3): 20-26.
[cited by applicant]
Chen et al., “Discordant protein and mRNA expression in lung adenocarcinomas”, Molecular & Cellular Proteomics, 2002, vol. 1, pp. 304-313.
[cited by applicant]
Cheville et al., “Gene Panel Model Predictive of Outcome in Men at High-Risk of Systemic Progression and Death From Prostate Cancer After Radical Retropubic Prostatectomy”, Journal of Clinical Oncology, 2008, vol. 26, N…
[cited by applicant]
Cooperberg et al., “Validation of a cell-cycle progression gene panel to improve risk-stratification in a contemporary prostatectomy cohort”, Journal of Urology, Apr. 2012, vol. 187, No. 4, Suppl. S, p. E850.
[cited by applicant]
Cortes et al., “Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art”, Translational Lung Cancer, 2015, vol. 4, No. 2, pp. 191-197.
[cited by applicant]
Cuzick et al., “Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort,” British Journal of Cancer, Mar. 13, 2012, vol. 106, No. 6, pp. 1095-109…
[cited by applicant]
Cuzick et al., “Prognostic value of an RNA expressive signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study,” The Lancet, Mar. 1, 2011, vol. 12, pp. 245-255.
[cited by applicant]
Dai et al., “A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients”, Cancer Research, May 15, 2005, vol. 65, No. 10, pp. 4059-4066.
[cited by applicant]
Ding et al., Cancer Research, vol. 71, No. 15, 2011.
[cited by applicant]
Dorey et al., “In Brief: The P Value: What Is It and What Does It Tell You?”, Clinical Orthopaedics and Related Research, vol. 468, No. 8, May 25, 2010, pp. 2297-2298.
[cited by applicant]
European Search Report and Written Opinion issued in corresponding EP Application No. 16170659.3, dated Dec. 13, 2016 (8 pages).
[cited by applicant]
European Search Report and Written Opinion issued in corresponding EP Application No. 18209293.2, dated May 16, 2019 (11 pages).
[cited by applicant]
Foley et al., “Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease”, Endocrine-Related Cancer, 2004, vol. 11, No. 3, pp. 477-488.
[cited by applicant]
Freedland et al., “Prognostic Utility of Cell Cycle Progression Score in Men with Prostate Cancer After Primary Externa Beam Radiation Therapy”, International Journal of Radiation, vol. 86, No. 5, Aug. 1, 2013, pp. 848-…
[cited by applicant]
Freije et al., “Gene expression profiling of gliomas strongly predicts survival”, Cancer Research, Sep. 15, 2004, vol. 64, No. 18, pp. 6503-6510.
[cited by applicant]
Galea et al., “The Nottingham Prognostic Index in primary breast cancer”, Breast Cancer Research and Treatment, 1992, vol. 22, No. 3, pp. 207-219.
[cited by applicant]
Gao et al., “G1 phase-dependent expression of Bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells”, Molecular Pharmacol., 2000, vol. 58, No. 5, pp. 1001-1010.
[cited by applicant]
Glinsky et al., “Gene expression profiling predicts clinical outcome of prostate cancer,” Journal Of Clinical Investigation, Mar. 1, 2004, vol. 113, No. 6, pp. 913-923.
[cited by applicant]
Groskopf et al., “APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer”, Clinical Chemistry, vol. 52, 2006, pp. 1089-1095.
[cited by applicant]
Gulzar et al., “Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1”, Oncogene, vol. 32, No. 1, 2013, pp. 70-77.
[cited by applicant]
Habel et al., “A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients”, Breast Cancer Research, vol. 8, No. 3, May 31, 2006, R25.
[cited by applicant]
Halvorsen et al., “Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer”, Clinical Cancer Research, vol. 9, A…
[cited by applicant]
Han et al., Urologic Oncology, 2013, vol. 1, No. 1, pp. 72-82.
[cited by applicant]
Henshall et al., Survival Analysis of Genome-Wide Gene Expression Profiles of Prostate Cancers Identifies New Prognostic Targets of Disease Relapse, Cancer Research, Jul. 15, 2003, vol. 63, pp. 4196-4203.
[cited by applicant]
Hess et al., “Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer”, Journal of Clinical Oncology, vol. 24, No. 26, S…
[cited by applicant]
Hessels et al., “The use of PCA3 in the diagnosis of prostate cancer”, Nat Rev Urol. May 2009;6(5):255-61. doi: 10.1038/nrurol.2009.40.
[cited by applicant]
Ho et al., “Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy”, Lung Cancer, vol. 59, 2…
[cited by applicant]
Holzbeirlein et al. Am J Pathol. 2004. 164: 217-227.
[cited by applicant]
Hughes et al., “Topoisomerase II—expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma”, J. Clin Pathol, vol. 59, 2006, pp. 721-724.
[cited by applicant]
International Search Report and Written Opinion from Application No. PCT/US2012/051447, dated Feb. 21, 2013.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding International Application No. PCT/US2010/020397, dated Mar. 9, 2010 (10 pages).
[cited by applicant]
Ishibashi et al., “Detection of significant prognostic factors using gene-expression profiling in patients with esophageal squamous cell carcinoma,” Gastroenterology, Apr. 2007, vol. 132, No. 4, Suppl. 2, p. A852.
[cited by applicant]
Juul et al. “Amount of Allelic Imbalance Predicts Response to Cisplatin in Breast and Ovarian Cancer”, Annals of Oncology, May 2010, 21, 1 page.
[cited by applicant]
Kerner et al., “Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology”, Gynecol. Oncol., vol. 99, No. 2…
[cited by applicant]
Kim et al., “Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma”, Hepatology. May 2012;55(5):1443-52. doi: 10.1002/hep.24813. Epub Mar. 18, 2012.
[cited by applicant]
Kosari et al., “Identification of Prognostic Biomarkers for Prostate Cancer”, Clinical Cancer Research, vol. 14, Mar. 15, 2008, pp. 1734-1743.
[cited by applicant]
Kuner et al., “Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes”, Lung Cancer, 2009, vol. 63, pp. 32-38.
[cited by applicant]
La Tulippe et al., “Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated with Metastatic Disease 1”, Cancer Research, vol. 62, Aug. 1, 2002, pp. 4499-4506.
[cited by applicant]
Lauss et al., “Consensus genes of the literature to predict breast cancer recurrence,” Breast Cancer Research and Treatment, Sep. 2007, vol. 110, No. 2, pp. 235-244.
[cited by applicant]
Lee et al., “Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression”, Clinical Cancer Research, vol. 14, No. …
[cited by applicant]
Lee et al., “Targeting prostate cancer based on signal transduction and cell cycle pathways”, Cell Cycle, Jun. 15, 2008, vol. 7, No. 12, pp. 1745-1762.
[cited by applicant]
Liu et al., “Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data,” BMC Medial Genomics, Sep. 11, 2008, vol. 1, No. 1, pp. 1-12.
[cited by applicant]
Liu et al., “Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis”, Journal of Zhejiang University Science B, vol. 8, No. 12, 2007, pp. 853-859.
[cited by applicant]
Loeb et al., “Overdiagnosis and Overtreatment of Prostate Cancer”, European Association of Urology, 2014, vol. 65, pp. 1046-1055.
[cited by applicant]
Ma et al, “Diagnostic and Prognostic Scoring System for Prostate Cancer Using Urine and Plasma Biomarkers”, Genetic Testing and Molecular Biomarkers, (Mar. 1, 2014), vol. 18, No. 3, doi: 10.1089/gtmb.2013.0424, ISSN 194…
[cited by applicant]
Ma et al., “Diagnostic and Prognostic Score System for Prostate Cancer Using Urine and Plasma Biomarkers” Genetic Testing and Molecular Biomarkers, vol. 18, No. 3, Mar. 1, 2014.
[cited by applicant]
Malhortra et al. Cancer Biology & Therapy. 2010. 10(10):955-960.
[cited by applicant]
McCall et al., “Is PTEN loss associated with clinical outcome measures in human prostate cancer?” British Journal of Cancer, Oct. 2008, vol. 99, No. 8, pp. 1296-1301.
[cited by applicant]
McDoniels-Silvers et al., “Differential Expression of Critical Cellular Genes in Human Lung Adenocarcinomas and Squamous Cell Carcinomas in Comparison to Normal Lung Tissues”, Neoplasia, 2002, vol. 4, No. 2, pp. 141-150.
[cited by applicant]
McDoniels-Silvers et al., “Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas”, Clinical Cancer Research, 2002, vol. 8, pp. 1127-1138.
[cited by applicant]
Michiels et al., “Prediction of cancer outcome with microarrays: a multiple random validation strategy”, Lancet, vol. 365, Feb. 5, 2005, pp. 488-492.
[cited by applicant]
Miller et al., “Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas”, Modern Pathology, Jul. 2004, 17(7):756-764.
[cited by applicant]
Miller et al., “Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas”, Modern Pathology, Jul. 2004, vol. 17, No. 7, pp. 756-764.
[cited by applicant]
Mosley et al., “Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists”, MBC Medical Genomics, Apr. 25, 2008, pp. 1-3.
[cited by applicant]
Mosley Jonathan D et al, “Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists”, BMC Medical Genomics, Biomed Central Ltd, London UK, (Apr. 25, 2008), vol. 1, No. 1, ISSN 1755-8794, p. 11…
[cited by applicant]
Mottet et al., “EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent”, European Association of Urology, 2017, vol. 71, No. 4, pp. 618-629.
[cited by applicant]
Nakagawa et al., “A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Denitive Prostate Cancer Therapy”, PLoS ONE, vol. 3, e2318, 2008, pp. 1-14.
[cited by applicant]
Nakopoulou et al., “Predictive Value of Topoisomerase IIa Immunostaining in Urothelial Bladder Carcinoma”, J. Clin. Pathol., vol. 54, 2001, pp. 309-313.
[cited by applicant]
Ohl et al., Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?, Journal of Molecular Medicine vol. 83, pp. 1014-1024 (Year: 2005).
[cited by applicant]
Oligo Ge Array. Human Breast Cancer Biomarkers Microarray. Jul. 16, 2006 [online]. [retrieved on Feb. 9, 2010). Retrieved from the internet: <URL: http://web.archive.org/web/20060716064356/www.superarray.com/gene_array …
[cited by applicant]
Oligo Ge Array. Human Cell Cycle Microarray. Jun. 11, 2006 [online). [retrieved on Feb. 9, 2010). Retrieved from the internet: <URL: http://web.archive.org/web/20061105215154/www.superarray .com/gene_array _producVHTMUO…
[cited by applicant]
Paik et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer”, New England Journal of Medicine, 2004, vol. 351, pp. 28174-2826.
[cited by applicant]
Pascal et al., “Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate”, BMC Genomics, vol. 9, No. 246, May 23, 2008.
[cited by applicant]
Pena-Diaz et al. Nucleic Acids Research. 2013.41 (5):2846-2856 and Supplementary Dataset 1.(Year: 2013).
[cited by applicant]
Porter et al., Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proce…
[cited by applicant]
PubMed search results for “microarray AND expression and mRNA”, 2019, pp. 1-3.
[cited by applicant]
Quinn et al., “Molecular markers of prostate cancer outcome,” European Journal of Cancer, Apr. 1, 2005, vol. 41, No. 6, pp. 858-887.
[cited by applicant]
Rakha et al., “Stratification of resectable lung adenocarcinoma by molecular and pathological risk eliminators”, European Journal of Cancer, vol. 51, 2015, pp. 1897-1903.
[cited by applicant]
Romanuik et al., “Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts”, American Journal of Pathology, vol. 175, Dec. 1, 2009, pp. 2264-2276.
[cited by applicant]
Schmidt et al., “Asynchronous Growth of Prostate Cancer Is Reflected by Circulating Tumor Cells Delivered from Distinct, Even Small Foci, Harboring Loss of Heterozygosity of the PTEN Gene”, Cancer Research, vol. 66, Sep…
[cited by applicant]
Scholmm et al., “Value of Cell Cycle Progression (CCP) Score to Predict Biochemical Recurrence and Definitive Post-Surgical Pathology,” Journal of Urology, Apr. 1, 2013, vol. 189, No. 4, p. E404.
[cited by applicant]
Shariat et al., “Improved Prediction of Clinical Outcomes in Patients With Advanced Bladder Cancer Using a Panel of Four Cell Cycle Regulators,” European Urology Supplements, Mar. 1, 2009, vol. 8, No. 4, p. 256.
[cited by applicant]
Shedden et al., “Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study”, Nature Medicine, vol. 14, No. 8, Aug. 2008, pp. 822-827.
[cited by applicant]
Sheikh et al., “Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study”, Neoplasia, vol. 10, No. 9, Sep. 2008, pp. 949-953.
[cited by applicant]
Shore et al., “Impact of the cell cycle progression test on physician and patient treatment selection for localized prostate cancer”, The Journal of Urology, 2016, vol. 195, No. 3, pp. 612-618.
[cited by applicant]
Simon et al., Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray Data, British Journal of Cancer, Jan. 1, 2003, vol. 89, No. 9, p. 1599-1604.
[cited by applicant]
Singh et al., “Combinatorial androgen receptor targeted therapy for prostate cancer”, Endocr Relat Cancer., 2006, 13(3):653-66.
[cited by applicant]
Slonim et al., “From patterns to pathways: gene expression data analysis comes of age”, Nature Genetics Supplement, 2002, vol. 32, pp. 502-508.
[cited by applicant]
Sotiriou et al, “Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis”, Journal of the National Cancer Institute, vol. 98, No. 4, Feb. 15, 2006, pp. 262-…
[cited by applicant]
Stephenson et al., “Integration of Gene Expression Profiling and Clinical Variables to Predict Prostate Carcinoma Recurrence after Radical Prostatectomy”, American Cancer Society, vol. 104, 2005, pp. 290-298.
[cited by applicant]
Stephenson et al., “Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy”, Journal of Clinical Oncology, Oct. 1, 2005, vol. 23, No. 28, pp. 7005-7012.
[cited by applicant]
Stone et al., “PTEN expression predicts biochemical recurrrence in prostate cancer”, American Association for Cancer Research, Apr. 2010, vol. 51, p. 287, XP009174127.
[cited by applicant]
Stone et al., ASCO-GU, 2017, Abstract 249, pp. 1.
[cited by applicant]
Subramanian et al., “Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?”, Journal of the National Cancer Institute, vol. 102, No. 7, 2010, pp. 464-474.
[cited by applicant]
Tabach et al., The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation, Molecular Systems Biology, 2005, pp. 1-15.
[cited by applicant]
Teschendorff et al., “A consensus prognostic gene expression classifier for ER positive breast cancer”, Genome Biology, vol. 7, Issue 10, Oct. 31, 2006, pp. 1-13.
[cited by applicant]
Toillon et al., “Estrogens decrease Y-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53”, International Journal of Radiation Oncology, Biology, Physics, vol. 67, No. …
[cited by applicant]
User Bulletin Applied Biosystems TaqMan Low Density Array, pp. 1-24 (Year: 2006).
[cited by applicant]
Van De Vijver et al., “A Gene-Expression Signature as a Predictor of Survival in Breast Cancer”, The New England Journal of Medicine, vol. 347, No. 25, Dec. 19, 2002, pp. 1999-2009.
[cited by applicant]
Venet et al., “Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome”, PLoS Computational Biology, vol. 7, No. 10, 2011, pp. e100240.
[cited by applicant]
Wang et al., “Gene networks and microRNAs implicated in aggressive prostate cancer,” Cancer Research, Dec. 15, 2009, vol. 69, No. 24, pp. 9490-9497.
[cited by applicant]
Wang et al., “Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer”, The Lancet, vol. 365, Feb. 19, 2005, pp. 671-679.
[cited by applicant]
Whitfield et al, “Identification of Genes Periodically Expressed in the Human Cell Cycle and Their Expression in Tumors”, Molecular Biology of the Cell, vol. 13, Jun. 2002, pp. 1977-2000.
[cited by applicant]
Willman et al., “Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate”, The Prostate, 2000, vol. 42, No. 4, pp. 280-286.
[cited by applicant]
Wistuba et al., “Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma”, Clinical Cancer Research, Nov. 15, 2013, vol. 19, No. 22, pp. 6261-6271.
[cited by applicant]
Wondergem et al., “Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma”, American Association for Cancer Research, Sep. 2012.
[cited by applicant]
Wu et al., “Cdc6 and Cyclin E2 Are PTEN-Regulated Genes Associated with Human Prostate Cancer Metastasis”, Neoplasia, vol. 11, No. 1, Jan. 2009, pp. 66-76.
[cited by applicant]
Wu et al., “Development and validation of a 32-gene prognostic index for prostrate cancer progression”, PNAS USA, 2013, vol. 110, No. 9, pp. 6121-6125 + Supplement pp. 1-9.
[cited by applicant]
Xie et al., “Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker”, The International Journal of Biochemistry and Cell Biology, vol. 47, 2014, pp. 112-117.
[cited by applicant]
Yanaihara et al., “Unique microRNA molecular profiles in lung cancer diagnosis and prognosis”, Cancer Cell, 2006, vol. 9, No. 3, pp. 189-198.
[cited by applicant]
Yoshimoto et al., “FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome”, British Journal of Cancer, vol. 97, 2007, pp. 678-685.
[cited by applicant]
Yu et al., “Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy”, Journal of Clinical Oncology, 2004, vol. 22, No. 14, pp. 2790-2799.
[cited by applicant]
Zhang et al., The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 34, No. 3, 2013.
[cited by applicant]
Zhu et al., “Rad9 Has Functional Role in Human Prostate Carcinogenesis”, Cancer Research, vol. 68, No. 5, Mar. 1, 2008, pp. 1267-1274.
[cited by applicant]
Bernier et al., “Radiation oncology: a century of achievements”, Nat Rev Cancer, 4(9):737-47, Sep. 2004.
[cited by applicant]
Fowler et al., “A challenge to traditional radiation oncology”, Int J Radiat Oncol Biol Phys, 60(4):1241-56, Nov. 15, 2004.
[cited by applicant]
Jones et al., “Phase III comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer”, J Clin Oncol, 24(34):5381-7, Dec. 1, 2006.
[cited by applicant]
O'Connor et al., “Therapeutic options and treatment of muscle invasive bladder cancer”, Expert Rev Anticancer Ther, 1(4):511-22, Dec. 2001.
[cited by applicant]
Lu et al., “TaqMan low density array is roughly right for gene expression quantification in colorectal cancer”, Clin Chim Acta, 389(1-2), pp. 146-151, Mar. 2008.
[cited by applicant]